Vor Bio's telitacicept receives NMPA conditional approval for IgA nephropathy in China

China's NMPA conditionally approved telitacicept for IgA nephropathy, marking the first BAFF/APRIL-targeting therapy approved for this indication and the fourth approval for the drug. The approval, based on positive Phase 3 TELIGAN results, validates the dual mechanism and supports Vor Bio's global development strategy for multiple autoimmune diseases.